Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new,
highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered
to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the
patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize
presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were
given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell
Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization.
The report summarizes major pharmaceutical companies developing these novel therapies and provides
challenges and perspectives for future therapeutic developments.
Keywords: Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.
Rights & PermissionsPrintExport